Bridging HealthTech and Life Sciences VEEV & IQV Strategic Outlook Post-Settlement

研报英文原文证据摘录

Bridging HealthTech and Life Sciences VEEV & IQV Strategic Outlook Post-Settlement

uidance and no “massive transformation” expected). On

the commercial side, IQVIA is transitioning OCE CRM by licensing the OCE CRM

software to Salesforce and collaborating on Salesforce’s next-generation Life Sciences

Cloud (including an undisclosed revenue share agreement), while continuing to market

and support OCE CRM for existing customers through 2029 (the legacy OCE business

is ~$150M in revenue). In parallel, the IQVIA–Veeva partnership establishes third‑party

access arrangements that expand the use of IQVIA data within Veeva applications and

allow Veeva data to be incorporated into IQVIA’s commercial offerings, supported by

IQVIA’s participation in Veeva’s partner programs.

• Where the two compete. Competitive overlap is narrowing in CRM as IQVIA’s OCE

winds down (2029 end of life), shifting the decision increasingly toward Veeva Vault

CRM vs. Salesforce Life Sciences Cloud. The core battleground remains data &

analytics, including Veeva’s Compass/data solutions vs. IQVIA longitudinal datasets,

Nitro vs. Connected Intelligence, and OpenData vs. OneKey. In digital trials, overlap

exists across broader workflows, but competitive intensity varies by module given

Veeva’s unified software platform approach vs. IQVIA’s blend of technology and CRO

delivery.

• Where the two collab. Post-settlement, collaboration has been reinstated across clinical,

commercial, and technology/AI, supported by a clearer interoperability framework.

Clinically, IQVIA joined Veeva’s CRO Clinical Data Partner program and can leverage

Veeva’s Clinical Suite (including Vault EDC) to execute trials for shared clients, targeting

faster database builds, study locks, and data delivery.